Back to results
US 2020/0002334 A1Published application
Inhibitors of (alpha-v)(beta-6) integrin
AssigneeMorphic Therapeutic, Inc.
InventorsBryce A. Harrison, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
Life of this patent
Estimating the term…
Abstract
Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
Claims40
A compound represented by formula (I):
- A-B—C (I)
- wherein:
- A is
- B is absent, alkylene, -alkylene-(O);
- -alkylene-N(R)C(O)—, -alkylene-(heterocyclyl)-C(O)—, -alkylene-C(O)N(R)—, -alkylene-C(O)—, -alkylene-N(R)—, -alkylene-N(R)C(O)N(R)—, -alkylene-N(R)SO2—, -alkylene-(aryl)-, -alkylene-(heterocyclyl)-, alkylene-(heterocyclyl)-alkylene, -aryl-alkylene-N(R)C(O)—;
- -aryl-C(O)N(R)—, -aryl-N(R)C(O)—, -(heterocyclyl)-alkylene-, -heterocyclyl-alkylene-N(R)C(O)—;
- -heterocyclyl-C(O)N(R)—, —O-heterocyclyl-;
- -alkylene-O—;
- -heterocyclyl-C(O)—;
- cycloalkylene;
- or cycloalkylene-O—;
- C is
- R is H, alkyl, or aryl;
- R1 is independently H, alkyl, halide, alkoxy, CF3, OH, NO2, —N(H)R, or NH2;
- R2 is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cycloalkyl, -alkylene-alkoxy, alkoxy, —OH, -alkylene-aryl, heterocycloalkyl, —N(R)C(O)R4, —N(R)SO2R4—, —N(R)-aryl, or —N(R)-heteroaryl;
- R3 is independently alkyl, halide, alkoxy, CF3, OH, NO2, or NH2;
- R4 is alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkylene-heterocyclyl, -alkylene-N(R)C(O)R5, or -alkylene-N(R)—SO2Me;
- R5 is alkyl, or cycloalkyl;
- R6 is H, or alkyl;
- X is C(Rc) or N;
- Rc is H, alkyl, aryl, OH, or halide;
- Rd is H, or (C1-C6)alkyl;
- a is independently 0, or 1;
- and
- b is 0, 1, 2, 3, or 4;
- or a pharmaceutically acceptable salt thereof.
23 more elements
Dependencies are inferred from the claim text.